NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP

The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Earlier this month the company filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock. "This reverse stock split, which should better align the company's capital structure with its stage of development, and an accompanying Nasdaq listing application, will represent a significant step toward creating long-term shareholder value and building ACT into a world-class player in the regenerative medicine space," said Gary Rabin, chairman and CEO of ACT.

PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. For the year ended December 31, 2011, PharmAthene recognized revenue of $24.3 million, compared to $21.0 million in 2010.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Excerpt from:
Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation